Abstract
Transforming growth factor (TGF)-β1 expression is induced upon liver injury, and plays a critical role in hepatic fibrosis. Antibodies against TGF-β1 represent a novel approach in the treatment of hepatic fibrosis. However, TGF-β1 is not a suitable antigen due to immunological tolerance. In the current study, we synthesized a multiple antigenic peptide (MAP) vaccine against the dominant B-cell epitope of TGF-β1. The immunogenicity and potential therapeutic effects of this vaccine were examined using a rat model of hepatic fibrosis. Dominant B-cell epitopes of TGF-β1 were identified using bioinformatic program. An MAP vaccine corresponding to the 90–98 amino acid domain of TGF-β1 and containing four dendritic arms was synthesized using a 9-fluorenylmethoxycarbonyl solid phase method. Hepatic fibrosis which was induced in male Sprague-Dawley rats received a high-fat diet and ethanol (1.8 g/kg). Starting from the third week, rats were exposed to 40 % carbon tetrachloride (CCl4; 150 μl/100 g body weight twice weekly, initially 200 μl/100 g) treatment for a duration of 8 weeks. Rats received the MAP vaccine (100 μg) or Freund’s adjuvant at weeks 1, 3, 5. A group of rats receiving the fibrosis-inducing regimen alone and a group of healthy rats (receiving an olive oil vehicle alone) were included as controls. At the conclusion of the experiment, serum titre of TGF-β1 antibody was measured using ELISA and a standard liver functional test panel was examined. The extent of hepatic fibrosis was determined by measuring hydroxyproline content in the liver as well as hematoxylin–eosin (HE) and van Gieson (VG) staining. The expression of TGF-β1 and alpha-smooth muscle actin (α-SMA) was examined using immunohistochemistry, and presented as positive staining cells. The MAP purity was >90 % upon reverse phase high-performance liquid chromatography, with apparent molecular weight at 4.77 kDa. Serum TGF-β1 antibody titre was 1:256. The fibrosis-inducing treatment produced significant liver damage, as reflected by increases in liver functional test, HE and VG staining. The MAP vaccine attenuated such damage, as reflected by decreased alanine aminotransferase, aspartate aminotransferase, total bilirubin, and hepatic hydroxyproline (116.78 ± 23.76 vs. 282.71 ± 136.94 IU/L; 319.78 ± 82.48 vs. 495.29 ± 137.13 IU/L; 2.02 ± 0.27 vs. 4.01 ± 0.52 μmol/L; 263.67 ± 41.18 vs. 439.14 ± 43.29 μg/g vs. in model rats, respectively; p < 0.01), as well as fibrosis extent by HE and VG staining. The MAP vaccine reduced TGF-β1 and α-SMA expression in rats (0.325 ± 0.059 vs. 0.507 ± 0.044 IOD/area; 0.318 ± 0.058 vs. 0.489 ± 0.029 IOD/area vs. model rats, respectively; p < 0.05). The TGF-β1 MAP vaccine could generate sufficient antibody that suppresses the development of hepatic fibrosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209–218
Berger CM, Knutson KL, Salazar LG et al (2004) Peptide-based vaccines, handbook of cancer vaccines. Humana Press Inc, Totowa
Bonafoux D, Lee WC (2009) Strategies for TGF-beta modulation: a review of recent patents. Expert Opin Ther Pat 19:1759–1769
Branton MH, Kopp JB (1999) TGF-beta and fibrosis. Microbes Infect 1:1349–1365
Cassidy Brady KK, Taylor W, Patkar A et al (2012) Carrier protein outsourcing. BioProcess Int 10:50–55
Chackerian B, Lowy DR, Schiller JT (2001) Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 108:415–423
Cheng K, Yang N, Mahato RI (2009) TGF-beta1 gene silencing for treating liver fibrosis. Mol Pharm 6:772–779
Ciesielski MJ, Kazim AL, Barth RF et al (2005) Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother 54:107–119
Delavallee L, Le Buanec H, Bessis N et al (2008) Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 67:1332–1338
Dong MX, Jia Y, Zhang YB et al (2009) Emodin protects rat liver from CCl(4)-induced fibrogenesis via inhibition of hepatic stellate cells activation. World J Gastroenterol 15:4753–4762
Edwards CA, O’Brien WD Jr (1980) Modified assay for determination of hydroxyproline in a tissue hydrolyzate. Clin Chim Acta 104:161–167
Flanders KC, Roberts AB, Ling N et al (1988) Antibodies to peptide determinants in transforming growth factor beta and their applications. Biochemistry 27:739–746
Gressner AM, Weiskirchen R, Breitkopf K et al (2002) Roles of TGF-beta in hepatic fibrosis. Front Biosci 7:d793–d807
Gressner OA, Rizk MS, Kovalenko E et al (2008) Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go? J Gastroenterol Hepatol 23(7 Pt 1):1024–1035
Grütter C, Wilkinson T, Turner R et al (2008) A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions. Proc Natl Acad Sci USA 105:20251–20256
Guan Q, Ma Y, Hillman CL et al (2009) Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis. Vaccine 27:7096–7104
Guo YH, Hao ZM, Luo JY et al (2006) Detecting the activity of antibodies induced by recombinant TGFbeta1 vaccine. Zhonghua Gan Zang Bing Za Zhi 14:183–186
Häkkinen HM, Franssila K, Kulonen E (1975) Effect of long-term administration of ethanol to the rat: lipids, collagen and other proteins, and Mallory bodies in the liver. Scand J Clin Lab Invest 35:753–765
James OF, Day CP (1998) Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 29:495–501
Kisseleva T, Brenner DA (2006) Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 21(Suppl 3):S84–S87
Kopf M, Bachmann MF, Marsland BJ (2010) Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 9:703–718
Leroux-Roels G (2010) Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28(Suppl 3):C25–C36
Li S, Peng L, Zhao W et al (2011) Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses. Vaccine 29:3695–3702
Liu X, Hu H, Yin JQ (2006) Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 26:8–22
Neninger Vinageras E, de la Torre A, Osorio Rodriguez M et al (2008) Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26:1452–1458
Paramasivam Saravanan SS, Kumar D (2009) Synthesis of highly immunogenic multiple antigenic peptides for epitopes of viral antigen to use in ELISA. Int J Peptide Res Ther 15:313–321
Pinzani M, Rombouts K (2004) Liver fibrosis: from the bench to clinical targets. Dig Liver Dis 36:231–242
Pohlers D, Brenmoehl J, Loffler I et al (2009) TGF-beta and fibrosis in different organs - molecular pathway imprints. Biochim Biophys Acta 1792:746–756
Shek FW, Benyon RC (2004) How can transforming growth factor beta be targeted usefully to combat liver fibrosis? Eur J Gastroenterol Hepatol 16:123–126
Sonderegger I, Rohn TA, Kurrer MO et al (2006) Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol 36:2849–2856
Song YH, Zhou XM, Xue XN et al (2005) Effect of ribozyme against transforming growth factor beta1 on biological character of activated HSCs. IUBMB Life 57:31–39
Spohn G, Keller I, Beck M et al (2008) Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol 38:877–887
Sun J, Wu D, Xu T et al (2009) SEPPA: a computational server for spatial epitope prediction of protein antigens. Nucleic Acids Res 37(Web Server issue):W612–W616
Szabo H, Fiorino G, Spinelli A et al (2010) Review article: anti-fibrotic agents for the treatment of Crohn’s disease - lessons learnt from other diseases. Aliment Pharmacol Ther 31:189–201
Tam JP (1988) Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 85:5409–5413
Tam JP (1996) Recent advances in multiple antigen peptides. J Immunol Methods 196:17–32
Tandon A, Tovey JC, Sharma A et al (2010) Role of transforming growth factor beta in corneal function, biology and pathology. Curr Mol Med 10:565–578
Tu CT, Guo JS, Wang M et al (2007) Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury. J Gastroenterol Hepatol 22:877–884
Ueno H, Sakamoto T, Nakamura T et al (2000) A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. Hum Gene Ther 11:33–42
Wang TT, Tan GS, Hai R et al (2010) Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA 107:18979–18984
Willemin G, Roger C, Bauduret A et al (2013) Major histocompatibility class II pathway is not required for the development of nonalcoholic fatty liver disease in mice. Int J Endocrinol 2013:972962
Wolff RA, Ryomoto M, Stark VE et al (2005) Antisense to transforming growth factor-beta1 messenger RNA reduces vein graft intimal hyperplasia and monocyte chemotactic protein 1. J Vasc Surg 41:498–508
Wu DF, Cederbaum AI (2009) Oxidative stress and alcoholic liver disease. Semin Liver Dis 29:141–154
Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214:199–210
Wynn TA, Barron L (2010) Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 30:245–257
Xu W, Wang LW, Shi JZ et al (2009) Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by Concanavalin A in mice. Hepatobiliary Pancreat Dis Int 8:300–308
Yata Y, Gotwals P, Koteliansky V et al (2002) Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology 35:1022–1030
Zhang J, Wang H, Yu H (2007) Thioacetamide-induced cirrhosis in selenium-adequate mice displays rapid and persistent abnormity of hepatic selenoenzymes which are mute to selenium supplementation. Toxicol Appl Pharmacol 224:81–88
Acknowledgments
We thank the staff members of the Medical Experimental Animal Center, School of Medicine, Xi’an Jiaotong University and the Department of Genetics and Molecular Biology, School of Medicine, Xi’an Jiaotong University.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Li, Y., Wang, W., Jia, X. et al. A Targeted Multiple Antigenic Peptide Vaccine Augments the Immune Response to Self TGF-β1 and Suppresses Ongoing Hepatic Fibrosis. Arch. Immunol. Ther. Exp. 63, 305–315 (2015). https://doi.org/10.1007/s00005-015-0333-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00005-015-0333-2